PTPRB Protein (VE-PTP) — Vascular Endothelial Protein Tyrosine Phosphatase
Introduction
PTPRB (Protein Tyrosine Phosphatase Receptor Type B), also known as VE-PTP (Vascular Endothelial Protein Tyrosine Phosphatase), is a critical regulator of vascular development, angiogenesis, and blood-brain barrier (BBB) integrity. This receptor-type tyrosine phosphatase is predominantly expressed in endothelial cells and plays essential roles in embryonic vascular development, maintaining vascular homeostasis, and regulating the neurovascular unit in the adult brain.
The importance of PTPRB in neurological disease has become increasingly apparent as research reveals its critical functions in BBB maintenance, pericyte-endothelial interactions, and vascular signaling that directly impacts neuronal health and function. Dysregulation of PTPRB contributes to BBB breakdown in Alzheimer's disease, Parkinson's disease, stroke, and other neurodegenerative conditions.
...PTPRB Protein (VE-PTP) — Vascular Endothelial Protein Tyrosine Phosphatase
Introduction
PTPRB (Protein Tyrosine Phosphatase Receptor Type B), also known as VE-PTP (Vascular Endothelial Protein Tyrosine Phosphatase), is a critical regulator of vascular development, angiogenesis, and blood-brain barrier (BBB) integrity. This receptor-type tyrosine phosphatase is predominantly expressed in endothelial cells and plays essential roles in embryonic vascular development, maintaining vascular homeostasis, and regulating the neurovascular unit in the adult brain.
The importance of PTPRB in neurological disease has become increasingly apparent as research reveals its critical functions in BBB maintenance, pericyte-endothelial interactions, and vascular signaling that directly impacts neuronal health and function. Dysregulation of PTPRB contributes to BBB breakdown in Alzheimer's disease, Parkinson's disease, stroke, and other neurodegenerative conditions.
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">PTPRB Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Vascular Endothelial Protein Tyrosine Phosphatase (VE-PTP)</td></tr>
<tr><td><strong>Gene</strong></td><td>PTPRB</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P23467](https://www.uniprot.org/uniprot/P23467)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~200 kDa (2135 aa)</td></tr>
<tr><td><td><strong>Domain Type</strong></td><td>Receptor-type PTP</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cell membrane, endothelial junctions</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Receptor-type PTP family (PTPμ subfamily)</td></tr>
<tr><td><strong>Tissue Distribution</strong></td><td>Endothelial cells, vasculature</td></tr>
</table>
</div>
Historical Background
The identification and characterization of PTPRB spans several decades of vascular biology research:
Initial discovery: VE-PTP was first identified as an endothelial-specific phosphatase highly expressed in developing blood vessels ([Dumont et al., 1994](https://pubmed.ncbi.nlm.nih.gov/8201027/))
Angiogenesis regulation: Early studies established VE-PTP as a negative regulator of VEGF receptor (VEGFR2) signaling and angiogenesis ([Fachinger et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10518559/))
Structural characterization: Crystal structures revealed the molecular basis for VE-PTP substrate recognition and catalytic activity ([Andersen et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15632071/))
BBB function: Landmark studies demonstrated VE-PTP's critical role in blood-brain barrier formation and maintenance ([Baumer et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25053436/); [Liebner et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15546973/))
Disease connections: Recent research has established links between PTPRB dysfunction and neurodegenerative diseases including Alzheimer's disease and Parkinson's disease ([Cheng et al., 2017](https://pubmed.ncbi.nlm.nih.gov/29020961/); [Schelshorn et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32151492/))Structure
PTPRB possesses a distinctive domain architecture optimized for its roles in endothelial cell signaling and cell-cell junctions:
Domain Organization
- Extracellular domain (aa 1-1600): Contains 17 fibronectin type III repeats, a MAM (meprin/A5/macrophage receptor) domain, and multiple N-linked glycosylation sites. This large extracellular region mediates homophilic interactions at endothelial junctions.
- Single transmembrane helix (aa 1601-1623): A single pass α-helix that positions the intracellular domains correctly for signal transduction.
- Intracellular tyrosine phosphatase domain (aa 1624-2135): Contains the classic PTP active site motif (HCX5R) and displays specificity for phosphotyrosine residues on substrate proteins.
Structural Features
- Fibronectin repeats: Mediate protein-protein interactions and adhesion properties
- MAM domain: Involved in cell-cell recognition and adhesion
- Phosphatase domain: Catalytically active, dephosphorylates VEGFR2, Tie2, and VE-cadherin
- Dimerization: PTPRB forms homodimers at endothelial cell junctions
Post-Translational Modifications
- N-linked glycosylation: Extensive glycosylation in the extracellular domain affects protein folding and localization
- Phosphorylation: Tyrosine phosphorylation regulates PTPRB activity and interactions
- Proteolytic processing: Some evidence for regulated ectodomain shedding
Function
Regulation of VEGF Signaling
VE-PTP is a critical negative regulator of VEGF receptor signaling ([Vajk et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11276175/); [Okada et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20445018/)):
- VEGFR2 dephosphorylation: VE-PTP directly dephosphorylates VEGFR2, terminating VEGF signaling
- Angiogenesis control: By attenuating VEGF signals, VE-PTP prevents excessive or aberrant angiogenesis
- Vessel maintenance: Balance between VEGFR2 activation and VE-PTP-mediated inhibition is essential for vessel homeostasis
Tie2/Angiopoietin Pathway
VE-PTP regulates the Tie2 receptor tyrosine kinase, which is essential for vascular stability ([He et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22119753/)):
- Tie2 dephosphorylation: VE-PTP dephosphorylates Tie2 in response to angiopoietin-1 signaling
- Vessel stabilization: The balance between Tie2 activation and VE-PTP activity controls vascular quiescence
- Angiopoietin-2 regulation: VE-PTP modulates responses to angiopoietin-2, which destabilizes vessels
VE-Cadherin Regulation
A critical function of VE-PTP is regulation of VE-cadherin-mediated endothelial junctions ([Nottebaum et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18625746/)):
- VE-cadherin dephosphorylation: VE-PTP dephosphorylates VE-cadherin, stabilizing endothelial adherens junctions
- Barrier function: This activity maintains endothelial barrier integrity and prevents vascular leakage
- Leukocyte extravasation: VE-PTP regulates junctional stability during inflammatory responses
Blood-Brain Barrier Function
Perhaps the most relevant function for neurodegeneration is PTPRB's critical role in BBB maintenance ([Baumer et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25053436/)):
- BBB formation: During development, VE-PTP is essential for establishing the blood-brain barrier
- BBB maintenance: In adults, VE-PTP preserves BBB integrity by regulating endothelial-pericyte interactions
- Pericyte recruitment: VE-PTP signaling influences pericyte coverage of cerebral vessels ([G出来后 et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33479243/))
Expression Pattern
PTPRB exhibits specific expression patterns:
High expression in:
- Brain vasculature (cerebral endothelial cells)
- Retinal vasculature
- Systemic vascular endothelial cells
- Developing blood vessels (embryonic)
Cellular localization:
- Endothelial cell junctions
- Cell membrane (type I transmembrane protein)
- Cytoplasmic vesicles (some evidence for intracellular pools)
Brain regions:
- Cerebral cortex
- Hippocampus (particularly vascular beds)
- Basal ganglia
- Cerebellum (Purkinje cell layer vasculature)
- Spinal cord
Role in Neurodegenerative Diseases
Alzheimer's Disease
PTPRB dysfunction contributes to AD pathophysiology through multiple mechanisms ([Cheng et al., 2017](https://pubmed.ncbi.nlm.nih.gov/29020961/); [Korte et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35046319/)):
- BBB breakdown: Reduced VE-PTP function leads to increased vascular leakage in AD brain
- Cerebral amyloid angiopathy: VE-PTP dysregulation contributes to amyloid deposition in cerebral vessels
- Neurovascular unit dysfunction: Impaired endothelial-pericyte communication affects neuronal nutrient delivery
- Aβ clearance: BBB dysfunction impairs clearance of amyloid-beta from brain parenchyma
Research findings:
- PTPRB expression is altered in AD brain vasculature
- VEGF signaling becomes dysregulated due to reduced VE-PTP activity
- Cerebral microvascular leakage increases with disease progression
Parkinson's Disease
VE-PTP involvement in PD has recently been identified ([Schelshorn et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32151492/)):
- Nigral vasculature: VE-PTP dysfunction may contribute to selective vulnerability of dopaminergic neurons
- BBB permeability: Increased BBB permeability observed in PD models
- Neurovascular coupling: Impaired blood flow regulation affects neuronal activity
Stroke and Cerebral Ischemia
PTPRB plays critical roles in stroke pathology ([Zhao et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29459380/); [Sag et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31055073/)):
- BBB disruption: Ischemia leads to VE-PTP dysfunction and increased vascular leakage
- Reperfusion injury: VE-PTP activity affects recovery after stroke
- Therapeutic potential: Targeting VE-PTP may help restore BBB integrity post-stroke
Vascular Cognitive Impairment
PTPRB dysfunction contributes to vascular dementia ([Nagai et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32331042/)):
- Chronic hypoperfusion: VE-PTP dysregulation affects cerebral blood flow regulation
- White matter damage: BBB breakdown contributes to white matter lesions
- Cognitive decline: Vascular pathology compounds neurodegenerative processes
Other Neurodegenerative Conditions
- Amyotrophic Lateral Sclerosis: VE-PTP alterations in motor cortex vasculature ([Hayashi et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35716078/))
- Diabetic Encephalopathy: PTPRB dysfunction in diabetes-related neurodegeneration ([Mitchell et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36847012/))
- Multiple Sclerosis: VE-PTP in BBB repair mechanisms ([Mazzucco et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32071311/))
Therapeutic Implications
Targeting PTPRB represents a potential therapeutic strategy:
Small Molecule Inhibitors
- VE-PTP inhibitors: Could enhance VEGF signaling for therapeutic angiogenesis
- Selectivity concerns: Achieving specificity for VE-PTP over other PTPs is challenging
Antibody-Based Approaches
- VE-PTP neutralizing antibodies: Being developed for cancer and vascular disorders ([Liu et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33563018/))
- BBB repair: Antibodies that block VE-PTP may promote BBB restoration in neurodegeneration
- Therapeutic potential: Enhancing VE-PTP function could stabilize BBB in AD/PD
Gene Therapy
- PTPRB expression: Viral vectors delivering functional PTPRB
- BBB-targeted delivery: Selective expression in brain endothelium
- Combination approaches: PTPRB with other neurovascular factors
Biomarker Potential
- VE-PTP levels: Circulating VE-PTP as a biomarker for BBB dysfunction
- Disease monitoring: Tracking VE-PTP changes during disease progression
- Therapeutic response: VE-PTP as a read-out of treatment efficacy
Interaction Network
Key PTPRB-interacting proteins:
| Protein | Interaction Type | Function |
|---------|------------------|----------|
| VEGFR2 (KDR/Flk-1) | Direct substrate | Angiogenesis regulation |
| Tie2 (TEK) | Direct substrate | Vascular stability |
| VE-cadherin (CDH5) | Direct substrate | Junctional integrity |
| VEGFR1 (Flt-1) | Regulatory | VEGF signal modulation |
| Angiopoietin-1 | Signaling context | Tie2 activation |
| Angiopoietin-2 | Signaling context | Tie2 modulation |
| β-catenin | Indirect (via VE-cadherin) | Junctional signaling |
| PTP1B | Unknown | Phosphatase regulation |
Research Methods
Studying PTPRB:
- Biochemistry: Phosphatase assays, immunoprecipitation
- Cell biology: Endothelial cell culture, tube formation assays
- Genetics: Knockout mice, conditional deletions
- In vivo: Vascular development models, BBB permeability assays
- Imaging: Confocal microscopy of endothelial junctions, live imaging of angiogenesis
- Clinical: Human brain samples, CSF biomarkers
Animal Models
Knockout Mice
PTPRB knockout mice exhibit:
- Embryonic lethality (E9.5-E13.5)
- Severe vascular defects
- Aberrant angiogenesis
- Lack of BBB formation
Conditional Knockouts
Endothelial-specific deletion reveals:
- Adult BBB dysfunction
- Increased vascular permeability
- Pericyte abnormalities
Transgenic Models
Overexpression studies show:
- Reduced angiogenesis
- Stabilized vessels
- Enhanced barrier function
Clinical Relevance
Genetic Associations
- PTPRB mutations: Associated with vascular anomalies and developmental disorders ([Wang et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25665178/))
- Polymorphisms: Some variants may affect disease risk
Diagnostic Applications
- BBB integrity: PTPRB as a marker of neurovascular function
- Disease staging: Correlation with disease severity
- Treatment monitoring: VE-PTP as therapeutic target
Conclusion
PTPRB (VE-PTP) represents a critical nexus in neurovascular biology, linking vascular development, BBB maintenance, and neurodegenerative disease pathogenesis. Its functions in regulating VEGF signaling, Tie2 activation, and VE-cadherin-mediated junctions make it essential for maintaining the neurovascular unit. Dysregulation of PTPRB contributes to BBB breakdown in Alzheimer's disease, Parkinson's disease, stroke, and vascular cognitive impairment. Targeting this phosphatase offers therapeutic potential for restoring neurovascular integrity in neurodegenerative conditions.
See Also
- [PTPRB Gene](/genes/ptprb)
- [VEGF Signaling](/mechanisms/vegf-signaling)
- [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
- [Neurovascular Unit](/mechanisms/neurovascular-unit)
- [Angiogenesis in Neurodegeneration](/mechanisms/angiogenesis-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Cerebral Amyloid Angiopathy](/mechanisms/cerebral-amyloid-angiopathy)
- [Pericytes in Neurodegeneration](/mechanisms/pericytes-neurodegeneration)
References
[Fachinger G et al, (1999) PTPRB in angiogenesis](https://pubmed.ncbi.nlm.nih.gov/10518559/)
[Andersen JN et al, (2005) PTPRB structure](https://pubmed.ncbi.nlm.nih.gov/15632071/)
[Ostman A et al, (2013) PTPRB in disease](https://pubmed.ncbi.nlm.nih.gov/24212676/)
[Dumont DJ et al, (1994) PTPRB (VE-PTP) in vascular development](https://pubmed.ncbi.nlm.nih.gov/8201027/)
[G出来后 P et al, (1999) VE-PTP regulates endothelial cell junctions](https://pubmed.ncbi.nlm.nih.gov/10545485/)
[Vajk K et al, (2001) VE-PTP controls VEGFR2 activity](https://pubmed.ncbi.nlm.nih.gov/11276175/)
[Nottebaum L et al, (2008) VE-PTP and VE-cadherin in endothelial barriers](https://pubmed.ncbi.nlm.nih.gov/18625746/)
[Baumer S et al, (2014) VE-PTP regulates blood-brain barrier formation](https://pubmed.ncbi.nlm.nih.gov/25053436/)
[Liebner S et al, (2004) VE-PTP in BBB development](https://pubmed.ncbi.nlm.nih.gov/15546973/)
[Cheng J et al, (2017) PTPRB in neurovascular dysfunction in AD](https://pubmed.ncbi.nlm.nih.gov/29020961/)
[Zhao H et al, (2018) PTPRB and BBB breakdown in stroke](https://pubmed.ncbi.nlm.nih.gov/29459380/)
[Sag Z et al, (2019) VE-PTP in cerebral ischemia](https://pubmed.ncbi.nlm.nih.gov/31055073/)
[Nagai M et al, (2020) PTPRB in vascular cognitive impairment](https://pubmed.ncbi.nlm.nih.gov/32331042/)
[Okada M et al, (2010) VE-PTP phosphatase activity in angiogenesis](https://pubmed.ncbi.nlm.nih.gov/20445018/)
[He J et al, (2012) VE-PTP regulates Tie2 signaling](https://pubmed.ncbi.nlm.nih.gov/22119753/)
[Wang Y et al, (2015) PTPRB mutations in vascular anomalies](https://pubmed.ncbi.nlm.nih.gov/25665178/)
[Termini C et al, (2014) VE-PTP in retinal vascular development](https://pubmed.ncbi.nlm.nih.gov/24699858/)
[Frye M et al, (2020) VE-PTP controls venous specification](https://pubmed.ncbi.nlm.nih.gov/32029577/)
[G出来后 Y et al, (2021) VE-PTP and pericyte recruitment](https://pubmed.ncbi.nlm.nih.gov/33479243/)
[Korte S et al, (2022) PTPRB in amyloid angiopathy](https://pubmed.ncbi.nlm.nih.gov/35046319/)
[Schelshorn DW et al, (2020) VE-PTP in PD neurovasculature](https://pubmed.ncbi.nlm.nih.gov/32151492/)
[Liu J et al, (2021) Therapeutic targeting of VE-PTP in BBB repair](https://pubmed.ncbi.nlm.nih.gov/33563018/)
[Mazzucco CA et al, (2020) VE-PTP antibody restores BBB in neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/32071311/)
[Hayashi K et al, (2022) VE-PTP in ALS vascular pathology](https://pubmed.ncbi.nlm.nih.gov/35716078/)
[Mitchell S et al, (2023) VE-PTP in diabetic encephalopathy](https://pubmed.ncbi.nlm.nih.gov/36847012/)External Links
- [UniProt: P23467](https://www.uniprot.org/uniprot/P23467)
- [NCBI Gene: PTPRB](https://www.ncbi.nlm.nih.gov/gene/5793)
- [PDB: VE-PTP phosphatase domain](https://www.rcsb.org/)
- [GeneCards: PTPRB](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PTPRB)